SanBio Co. Reports Non-operating Expenses and Deferred Income Taxes

SanBio Co ( (JP:4592) ) has provided an update.

SanBio Co., Ltd. reported non-operating expenses and deferred income taxes for the first quarter of the fiscal year ending January 31, 2026. The company recorded a foreign exchange loss of 711 million yen and a foreign currency translation adjustment of 651 million yen due to exchange rate fluctuations. Additionally, 23 million yen was recorded in stock issuance expenses, and deferred income taxes of negative 219 million yen were recognized. These financial activities reflect the company’s ongoing financial management and could impact its earnings performance.

The most recent analyst rating on (JP:4592) stock is a Hold with a Yen1400.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.

More about SanBio Co

SanBio Co., Ltd. operates in the biotechnology industry, focusing on regenerative medicine and cell therapy products. The company is known for its innovative treatments targeting neurological disorders and aims to expand its market presence in the healthcare sector.

Average Trading Volume: 5,613,796

Technical Sentiment Signal: Buy

Current Market Cap: Yen265B

For detailed information about 4592 stock, go to TipRanks’ Stock Analysis page.